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Abstract
Background: Acinetobacter baumannii strains co-producing carbapenemase and 16S rRNA methylase are highly
resistant to carbapenems and aminoglycosides.
Methods: Ninety-three isolates of multidrug-resistant A. baumannii were obtained from an intensive care unit in a
hospital in Vietnam. Antimicrobial susceptibility tests and whole genome sequencing were performed. Multilocus
sequence typing and the presence of drug resistant genes were determined and a maximum-likelihood
phylogenetic tree was constructed by SNP alignment of whole genome sequencing data.
Results: The majority of isolates belonged to clonal complex 2 (ST2, ST570 and ST571), and carried carbapenemase
encoding genes blaOXA-23 and blaOXA-66. Two isolates encoded carbapenemase genes blaNDM-1 and blaOXA-58 and
the 16S rRNA methylase encoding gene armA and did not belong to clonal complex 2 (ST16).
Conclusion: A. baumannii isolates producing 16S rRNA methylase ArmA and belonging to clonal complex 2 are
widespread, and isolates co-producing NDM-1 and ArmA are emerging, in medical settings in Vietnam.
Keywords: Multidrug-resistance, Acinetobacter baumannii, 16S rRNA methylase ArmA, Metallo-β-lactamase NDM-1,
Intensive care unit
Background
Metallo-β-lactamases (MBLs) confer reduced susceptibility
to carbapenems, cephalosporins, and all penicillins except
monobactams [1]. Acquired MBLs are produced by several
Gram-negative bacterial strains, including Acinetobacter
spp., Pseudomonas aeruginosa, and several Enterobacteria-
ceae [1]. MBLs are categorized by their amino acid se-
quences into various types [2–4], including AIM [5], DIM
[6], FIM [7], GIM [8], IMPs [9], KHM [10], NDMs [11],
SMB [12], SIM [13], SPM [14], TMBs [15] and VIMs [16].
The most prevalent MBLs are IMP-, VIM-, and NDM-type
enzymes [1, 2, 17]. NDM-1 was initially isolated from Kleb-
siella pneumoniae and Escherichia coli in 2008 in Sweden
[11]. Between 2009 and 2012, 950 isolates of NDM-1-
producing bacteria, including 36 A. baumannii isolates,
were reported worldwide [18]. Subsequently, at least 13
NDM variants (www.lahey.org/studies) have been reported
in several countries [4, 19–30].
Aminoglycosides are effective antibiotics for the treat-
ment of infectious diseases caused by Gram-negative bac-
teria. These agents block bacterial protein synthesis by
binding to the 30S ribosomal subunit [31]. Methylation of
16S rRNA by 16S rRNA methylases, however, makes
Gram-negative bacteria highly resistant to all clinically im-
portant aminoglycosides [32]. In 2003, clinical isolates of
highly aminoglycoside-resistant Gram-negative bacteria
producing 16S rRNA methylases were identified in France
[33] and Japan [34]. Since then, 16S rRNA methylase-
producing Gram-negative bacteria have been isolated in
other parts of the world, including Asian countries, such
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as Afghanistan, Bangladesh, China, Hong Kong, India,
Japan, Korea, Oman, and Pakistan [35].
Methods
Bacterial samples and drug susceptibility tests
From 2011 to 2013, 93 clinical isolates of A. baumannii
were obtained from respiratory tract samples taken from
patients hospitalized in an intensive care unit (ICU) in
Cho Ray Hospital in Ho Chi Minh City, Vietnam.
MICs of amikacin, arbekacin, ciprofloxacin, colistin,
imipenem, meropenem, and tigecycline were determined
using the microdilution method, as described [36].
Whole genome sequences
Genomic DNA from the 93 multidrug-resistant iso-
lates were extracted using DNeasy Blood & Tissue kits
(QIAGEN, Tokyo, Japan) and sequenced by MiSeq
(Illumina, San Diego, CA). MiSeq data, including total
length, number of contig, N50, average contig length
and % GC content, were shown in Additional file 1:
Table S1. To identify SNPs among these genomes, all reads
of each isolate were aligned against the A. baumannii
TYTH-1 sequence (Accession no. CP003856) using CLC
genomics workbench, version 5.5 (CLC bio, Tokyo, Japan).
SNP concatenated sequences were aligned by MAFFT
(http://mafft.cbrc.jp/alignment/server/). A maximum-
likelihood phylogenetic tree was constructed from the
SNP alignment with PhyML 3.0 [37]. The probability
of node branching was evaluated with 100 bootstrap-
pings. Raw reads of all isolates were assembled into
more than 500 bp contigs by CLC genomics workbench.
Contigs around drug-resistant genes were annotated
using the BLAST database (http://blast.ncbi.nlm.nih.-
gov/Blast.cgi?CMD=Web&PAGE_TYPE=BlastHome).
Multilocus sequence typing (MLST) based on contig
data was deduced using CLC genomics workbench, and
matched against the Institut Pasteur MLST (http://pub-
mlst.org/abaumannii/) databases. The result of STs ac-
cording to PubMLST (http://pubmlst.org/abaumannii/)
scheme was shown in Additional file 2: Table S2. Anno-
tations using the RAST server (http://rast.nmpdr.org/)
were performed to compare numbers of prophages and
resistance factors. All raw read data of the 93 isolates
have been deposited at GenBank as accession numbers
DRX032164 to DRX032256.
Ethical approval
The study protocol was carefully reviewed and ap-
proved by the ethics committee of Cho Ray Hospital
(approval number: 1644/QD-BVCR), the ethics com-
mittee of the National Center for Global Health and
Medicine (No. 1268), and the Biosafety Committee of
the National Center for Global Health and Medicine
(approval number: 27-M-52), respectively. Individual
informed consent was waived by the ethics committee
listed above because this study used currently existing
sample collected during the course of routine medical care
and did not pose any additional risks to the patients.
Results
Drug susceptibility tests
The majority of the A. baumannii isolates tested were
highly resistant to carbapenems, aminoglycosides, and cip-
rofloxacin, but sensitive to colistin and tigecycline (Table 1).
MICs were 0.5 – > 512 μg/mL (MIC50 > 512 μg/mL and
MIC90 > 512 μg/mL) to amikacin, 32– > 512 μg/mL
(MIC50 > 512 μg/mL and MIC90 > 512 μg/mL) to ciproflox-
acin, 0.125–16 μg/mL (MIC50 = 0.5 μg/mL and MIC90 =
1 μg/mL) to colistin, 8–128 μg/mL (MIC50 = 32 μg/mL and
MIC90 = 64 μg/mL) to imipenem, 4 to 128 μg/mL
(MIC50 = 32 μg/mL and MIC90 = 64 μg/mL) to merope-
nem, and < 0.125–16 μg/mL (MIC50 = 1 μg/mL and
MIC90 = 8 μg/mL) to tigecycline. The isolate NCGM321
was particularly resistant to carbapenems and aminoglyco-
sides, with MICs of > 512 μg/mL to amikacin, > 512 μg/mL
to arbekaein, 512 μg/mL to ciprofloxacin, 0.25 μg/mL to
colistin, 128 μg/mL to imipenem, 64 μg/mL to meropenem,
and 2 μg/mL to tigecycline.
Molecular epidemiology and drug resistant genes
Phylogenic analysis based on SNP concatenation showed
that the 93 isolates belonged to seven clades, ST2 (28 iso-
lates), ST16 (two isolates), ST23 (seven isolates), ST215
(seven isolates), ST570 (19 isolates), ST571 (28 isolates),
and ST575 (11 isolates) (Fig. 1). The isolates in Clades ST2,
ST570, and ST571 belonged to worldwide clonal lineage II
Table 1 MIC50 and MIC90 values and antimicrobial resistance of the 93 A. baumannii isolates
Antimicrobial agents Breakpoint for resistance (mg/L) % Resistant Range (mg/L) MIC50 (mg/L) MIC90 (mg/L)
Imipenem ≥8 100 8–128 32 64
Meropenem ≥8 99 4–128 32 64
Amikacin ≥64 87 0.5 – > 512 >512 >512
Ciprofloxacin ≥4 100 32 – > 512 >512 >512
Colistin ≥4 5 0.125–16 0.5 1
Tigecycline - - ≤0.125–16 1 8
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(CC2, European Clone II) [38]. All isolates tested contained
intrinsic blaADC. No novel blaADC gene was detected. None
of the intrinsic blaADC genes contained ISAba1, which is re-
sponsible for the overexpression of these genes [39]. The
intrinsic blaADC genes encoded clade-specific blaOXA-51-like
variants, with the 71 isolates belonging to Clades ST2,
ST215, ST570, and ST571 having blaOXA-66, the 11 isolates
belonging to ST575 having blaOXA-144, the seven isolates
belonging to ST23 having blaOXA-68, and the two isolates
belonging to ST16 having blaOXA-51 (Table 2). The 2 iso-
lates belonging to ST16 also contained the blaNDM-1,
blaOXA-58, and blaVEB-1 genes. Of the all 93 isolates tested,
71 had blaTEM-1, 56 had blaOXA-23, and three had blaVEBs.
Among the 93 isolates, 77 had armA, 77 had aadA1, 34
had aac(6’)-Ib-cr, 28 had aph(3’)-Ia, 18 had aac(3)-Ia, 12
had aph(3’)-Via, 10 had aph(3’)-Vib, seven had aac(3)-Iid,
five had aphA6, and one had aac(3)-Ib. No plasmid was
detected in any of the 93 isolates, indicating that all drug
resistance genes were located on chromosomes.
Genomic environments surrounding armA, blaOXA-23
blaNDM-1, blaOXA-51-like, and blaOXA-58
The genetic environment surrounding armA in NCGM346
belonging to Clade ST571 (Accession no. LC030435) is
shown in Fig. 2a. This genetic environment, from nt 1 to nt
17,473, was more than 99.99 % homologous to the analo-
gous region of A. baumannii strains MDR-TJ isolated in
China [40] and NCGM253 isolated in Japan [41]. The
sequence surrounding armA from nt 5838 to nt 9879
was identical to the transposon Tn1548 (Accession no.
EU014811) detected in an A. baumannii isolate from
North America [42] and included the ISCR1 insertion
sequence. Putative transposase genes were located both
upstream (tnpU) and downstream (tnpD) of armA
(Fig. 2a). Four additional isolates, NCGM165, NCGM169,
NCGM175, and NCGM194, belonging to Clades ST570,
ST215, ST23, and ST2, respectively, had the same genetic
organization surrounding armA as the NCGM346 isolate.
None of these five isolates contained plasmids, indicating
that armA is chromosomally encoded in each.
The genetic environment surrounding blaNDM-1 in
NCGM321 belonging to Clade ST16 (Accession no.
LC032101) is shown in Fig. 2b. The blaNDM-1 gene was
located between two copies of ISAba125 and was carried
by the Tn125 composite transposon. The genetic envir-
onment surrounding blaNDM-1 was 100 % homologous
to those of A. baumannii strain IOMTU433 isolated
in Nepal (accession no. AP014649), A. baumannii
ZW85-1 plasmid pAbNDM-1 isolated in China (ac-
cession no. JN377410), Acinetobacter lwoffii WJ10621
Fig. 1 Molecular phylogeny of the 93 Acinetobacter baumannii
strains from patient isolates. Phylogenic analysis based on SNP
concatenation revealed seven clades, ST2, ST16, ST23, ST214, ST570,
ST571, and ST575. Isolates in Clades ST2, ST570, and ST571 belonged
to clonal complex 2 (CC2)
Table 2 MLST and drug resistance genes in A. baumannii isolates
MLST No. of isolatesa Carbapenemase and ESBL encoding genes Aminoglycoside-resistance genes
ST2 (CC2) 17 blaOXA-66, blaOXA-23 (9/17), blaPER-1 (1/17),
blaTEM-1 (16/17)
armA, aac(6’)-Ib-cr (13/17), aac(3)-Ia(1/17), aadA1 (14/17),
aph(3’)-Ia (14/17)
ST16 2 blaNDM-1, blaOXA-51, blaOXA-58, blaVEB-1,
blaTEM-1 (1/2)
armA (1/2), aac(3)-Iid, aadA1, aadB, aph(3’)-Via
ST23 7 blaOXA-23 (2/7), blaOXA-68, blaPER-1, blaTEM-1 (1/23) armA (3/7), aac(6’)-Ib-cr (4/7), aadA1 (3/7), aadB (1/7), aph(3’)-Ia (1/7),
aph(3’)-Via (5/7), aph(3’)-Vib (1/7), aphA6 (1/7)
ST215 7 blaOXA-23 (4/7), blaOXA-66, blaTEM-1 armA (6/7), aac(6’)-Ib (1/7), aac(6’)-Ib-cr (5/7), aac(3)-Ia (4/7), aadA1,
aph(3’)-Ia (5/7)
ST570 (CC2) 19 blaOXA-23 (9/19), blaOXA-66, blaTEM-1 (18/19) armA, aac(6’)-Ib (7/19), aac(6’)-Ib-cr (11/19), aac(3)-Ia, aadA1,
aph(3’)-Ia (7/19)
ST571 (CC2) 28 blaOXA-23 (22/28), blaOXA-66, blaPER-1 (5/28), blaTEM-1 armA, aac(3)-Iid (4/28), aadA1, aadB (2/28), aph(3’)-Via (1/28),
aph(3’)-Vib (4/28)
ST575 11 blaOXA-23 (9/11), blaOXA-144, blaPER-1, blaTEM-1 aadB (5/11), aph(3’)-Via (3/11), aph(3’)-Vib (4/11), aphA6 (4/11)
ST577 1 blaOXA-23, blaOXA-66, blaTEM-1 armA, aac(6’)-Ib, aac(3)-Ia, aadA1
ST578 1 blaOXA-51, blaOXA-58, blaVEB-7 aac(3)-Ib, aadA1, aph(3’)-Via
aTotal number of isolates belonging to the same sequence type
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plasmid pNDM-BJ01 isolated in China (accession no.
JQ001701), and A. baumannii 161/07 isolated in
Germany (accession no. HQ857107). The genetic envir-
onment surrounding blaNDM-1 in NCGM328, the second
isolate belonging to Clade ST16, was identical to the gen-
etic environment surrounding blaNDM-1 in NCGM321.
The genetic environment surrounding blaOXA-23 in
NCGM346 belonging to Clade ST571 was ISAba1-
blaOXA-23-yeeA (yeeA: ATPase encoding gene) and
was more than 99 % identical with chromosome sequences
of A. baumannii strains IOMTU433 (accession no.
AP014649) and NCGM237 [41]. The genetic organization
surrounding blaOXA-23 in four additional isolates,
NCGM165, NCGM169, NCGM175, and NCGM194, be-
longing to Clades ST570, ST215, ST23, and ST2, respect-
ively, was identical to that surrounding blaOXA-23 in
NCGM346.
The genetic environment surrounding blaOXA-51-like in
NCGM346 belonging to Clade ST571 was fxsA-blaOXA-
66-orf6-orf7-ruvC-orf8-gueG-bioB, where orf6 encodes
the enzyme phosphinothricin N-acetyltransferase, orf7
encodes an XRE family transcriptional regulator, and
orf8 encodes a hypothetical protein. The same genetic
organization surrounding blaOXA-51-like was observed
in four additional isolates, NCGM165, NCGM169,
NCGM175, and NCGM194, belonging to Clades
ST570, ST215, ST23, and ST2, respectively.
The genetic environment surrounding blaOXA-58 in
NCGM328 belonging to Clade ST16 was ISAba3-
blaOXA-58-orf9-orf10-ISAba3, where orf9 encodes a
transposon-related protein and orf10 encodes a hypo-
thetical protein. The structure was the same as a part of
Acinetobacter spp. M131 plasmid pM131-2 (accession
no. JX101647).
Structures of the genomic resistance islands of CC2
isolates
The resistance island (RI) of the isolate NCGM196 be-
longing to Clade ST2 contained two Tn6021-like copies
and one Tn5393-like copy. The resistance genes in the
RI included sul1, which encodes sulfonamide resistance
protein, and tetB and tetR, which regulate tetracycline
resistance, as well as the streptomycin resistance genes
strA and strB. The RI structure of the other ST2 isolate
(NCGM194) was identical to that of A. baumannii
MDT-TJ [40] and TYTH-1 [43]. RIs of the isolates
belonging to Clades ST570 (NCGM165) and ST571
(NCGM346) were identical to those of AbaR4 [44], a
compound transposon containing a Tn6022 backbone.
Prophages and resistance factors
The A. baumannii isolates had several transposable ele-
ments, phages/prophages and resistance factors. The
isolates belonging to international clone 2, including
NCGM165 (ST570), NCGM194 (ST2) and NCGM346
(ST571), had fewer phages/prophages than the isolates
belonging to other clones, including NCGM169 (ST215),
NCGM175 (ST23) and NCGM328 (ST16). The isolates
NCGM165, NCGM194, NCGM346, NCGM169, NCGM1
75, and NCGM328 contained 10, 18, 10, 8, 7, and 6 trans-
posable elements, respectively; 54, 60 80, 57, 57 and 57 re-
sistance factors, respectively; and 11, 8, 8, 27, 49 and 32
phages/prophages, respectively.
Discussion
To our knowledge, this is the first report of A. baumannii
isolates co-producing NDM-1 and ArmA emerging in a
medical setting in Vietnam. Enterobacteriaceae producing
only NDM-1 had been reported in Vietnam [18, 45, 46], in-
cluding NDM-1-producing K. pneumoniae isolated from
environmental samples [45] and NDM-1-producing En-
terobacteriaceae isolated from samples in a Vietnamese sur-
gical hospital [47]. There have been no reports of A.
baumannii co-producing NDM-1 and ArmA and belong-
ing to international clone 2, although NDM-1 producers
belonging to international clone2 were reported in East
Africa in 2013 [48]. It is important to continue the sur-
veillance of NDM-1-producing pathogens, including A.
baumannii, in medical settings in Vietnam.
The high prevalence of Gram-negative bacteria producing
ArmA in Vietnam may result from the inadequate use of
aminoglycosides in that country. An analysis of patients
hospitalized in Vietnam showed that 67.4 % received antibi-
otics, with 18.9 % receiving aminoglycosides, although
Fig. 2 Genetic environments of armA and blaNDM-1 in A. baumannii NCGM346 (a) and NCGM321 (b). orf1, gene encoding a hypothetical protein;
orf2, gene encoding a DNA-binding protein; orf3, gene encoding a DNA replication protein; orf4 and orf5, genes encoding hypothetical proteins
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30.8 % of the prescribed antibiotics were considered in-
appropriate [49]. This latter rate was higher than the rates
of inappropriately prescribed antibiotics in Malaysia
(4.0 %) [50], Turkey (14.0 %) [51], Hong Kong (20.0 %)
[52] and European countries (17.8–32.0 %) [53, 54].
A similar genetic environment surrounding blaNDM-1
has been reported in A. baumannii stains isolated in
China [55], Colombia (accession no. CP010399), France
[22], Germany [56] and the United States (accession no.
CP010370); in A. lwoffii isolated in China [57]; in E. coli
isolated in Colombia (accession no. CP010373); in K.
pneumoniae isolated in Colombia (CP010391) and the
United States [58]; and in Providencia rettgeri isolated in
Canada [59]. A similar environment surrounding armA
was reported in A. baumannii strains isolated in China
[40], Japan [41], and Nepal (accession no. AP014649).
The genetic organization of blaNDM-1 has spread world-
wide, whereas that of armA has spread in Asian countries.
A. baumannii isolates belonging to international clone
2 must have been disseminated throughout medical set-
tings in Vietnam, since 69.9 % of all isolates tested
belonged to this clone (ST2, ST570, and ST571). Epi-
demiological studies of A. baumannii isolates obtained
from a hospital in Hanoi are currently ongoing to clarify
whether A. baumannii isolates belonging to inter-
national clone 2 are disseminating throughout Vietnam.
The isolates belonging to Clades ST16, ST23, and ST215
were not identified as belonging to any previously de-
scribed international clones [38]. To date, one A. bauman-
nii isolate belonging to Clade ST16 was isolated in 2001 in
the Netherlands, 3 isolates belonging to ST23 were iso-
lated in the Netherlands (in 1964) and Sweden (in 2006
and 2007), and 6 isolates belonging to Clade ST215 were
isolated in 2008 in China. Clones ST570, ST571, and
ST575 were novel STs. Of the isolates belonging to CC2,
those in Clades ST570 and ST571 may have evolved in a
unique manner in Vietnam because the structures of re-
sistant islands in ST570 and ST571 isolates were different
from those in ST2 isolates.
Conclusions
This study showed that 16S rRNA methylase ArmA-
producing A. baumannii isolates belonging to clonal
complex 2 have spread, and that NDM-1-and ArmA-co-
producers not belonging to clonal complex 2 are emer-
ging, in medical settings in Vietnam.
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